What Adverse Effects Has Retatrutide Shown?

Retatrutide's clinical trials have reported mostly gastrointestinal side effects — nausea, vomiting, diarrhea and constipation — described as mild to moderate in severity and more frequent during dose escalation, according to the phase 2 obesity trial published by Jastreboff et al., NEJM 2023 and confirmed in the phase 3 trial by Jastreboff et al., NEJM 2026. Retatrutide is a triple agonist that activates the GLP-1, GIP and glucagon receptors, and that third receptor is what distinguishes its adverse-event pattern from single- or dual-receptor agonists already on the market.

What side effects showed up in the phase 2 trial?

The phase 2 trial from Jastreboff et al., NEJM 2023 tested retatrutide across a range of doses in adults with obesity. The most commonly reported adverse events were gastrointestinal — nausea, diarrhea, vomiting, constipation and reflux — and they followed a dose-dependent pattern: higher doses produced more events, concentrated in the initial escalation phase. Most of these episodes were classified as mild to moderate and tended to decrease over the course of treatment, a pattern already familiar from other GLP-1 agonists as the body adjusts to the drug. The trial also reported an increase in heart rate in the groups receiving higher doses, which the authors attributed to the glucagon component of the triple mechanism.

The batch of retatrutide used for laboratory analysis is covered on the retatrutide product page, where the purity reported by the testing laboratory is listed.

What changed in the phase 3 trial?

The phase 3 trial, also published by Jastreboff et al., NEJM 2026, enrolled a larger sample and followed participants for longer than the phase 2 trial. The adverse-event profile it reported was consistent with what the phase 2 trial had already shown: gastrointestinal symptoms predominated, incidence was highest during dose titration, and events tended to level off during the maintenance phase. No new or unexpected safety signals were described relative to phase 2 — a meaningful point, since a larger sample and longer follow-up are exactly what makes it possible to detect rare adverse events that a smaller phase 2 trial can miss.

What did the type 2 diabetes trial show?

Alongside the obesity studies, Rosenstock et al., Lancet 2023 evaluated retatrutide in adults with type 2 diabetes in a phase 2 trial. The adverse-event pattern was similar to the obesity trials — gastrointestinal, dose-dependent — with one additional consideration specific to this population: the risk of hypoglycemia, particularly relevant for participants who were also taking other glucose-lowering medications. That risk is a distinguishing factor between the diabetes trials and the obesity-only trials, where it does not apply the same way because most participants were not on other glucose-lowering drugs.

Were there cardiovascular or metabolic effects beyond the GI symptoms?

Beyond digestive discomfort, the finding that recurs across the obesity trials is an increase in heart rate associated with higher doses, described in both the phase 2 and the phase 3 trials of retatrutide. This is a known effect within the incretin-agonist class and prompted specific vital-sign monitoring during the trials. No clinically relevant signals of liver or kidney toxicity attributable to the drug have been reported in the studies published so far.

How many participants dropped out because of side effects?

In all three trials cited here, a share of participants discontinued treatment because of adverse events, most often gastrointestinal in origin and concentrated in the higher-dose groups. That dropout pattern — higher at higher doses, higher early in treatment — holds across the phase 2 obesity trial, the phase 3 trial and the type 2 diabetes trial, which suggests the drug's tolerability profile does not change substantially between populations or between phases of clinical development.

What is retatrutide's regulatory status today?

Retatrutide is not approved by the FDA. Based on the trials cited above, the molecule has completed phase 3 development for obesity, with those results already published by Jastreboff et al., NEJM 2026. Completing phase 3 is not the same as approval — it is the stage that, if the data hold up through the rest of the regulatory process, can lead to it.

PeptoClinic operates in the United States and supplies research-grade retatrutide with each batch analyzed by an outside laboratory, a process described on the quality page. A physician reviews each consultation before anything ships. The same batch-level documentation accompanies every market PeptoClinic serves, including the retatrutide page for Argentina, and current availability is listed on the pricing page.